OneDigital Investment Advisors LLC Sells 945 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

OneDigital Investment Advisors LLC decreased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 35.0% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,755 shares of the pharmaceutical company's stock after selling 945 shares during the period. OneDigital Investment Advisors LLC's holdings in Vertex Pharmaceuticals were worth $851,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of VRTX. Mascagni Wealth Management Inc. bought a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth approximately $31,000. Truvestments Capital LLC increased its stake in shares of Vertex Pharmaceuticals by 30.3% during the fourth quarter. Truvestments Capital LLC now owns 99 shares of the pharmaceutical company's stock worth $40,000 after purchasing an additional 23 shares during the period. Mpwm Advisory Solutions LLC bought a new position in Vertex Pharmaceuticals during the 4th quarter worth $40,000. Minot DeBlois Advisors LLC bought a new position in Vertex Pharmaceuticals during the 4th quarter worth $44,000. Finally, Prestige Wealth Management Group LLC increased its stake in Vertex Pharmaceuticals by 45.5% during the 4th quarter. Prestige Wealth Management Group LLC now owns 112 shares of the pharmaceutical company's stock worth $45,000 after acquiring an additional 35 shares during the period. Institutional investors own 90.96% of the company's stock.

Wall Street Analyst Weigh In

VRTX has been the topic of a number of recent research reports. Leerink Partners restated a "market perform" rating and set a $503.00 price objective (down previously from $550.00) on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Wolfe Research lowered Vertex Pharmaceuticals from an "outperform" rating to a "peer perform" rating in a research note on Wednesday, May 7th. The Goldman Sachs Group restated a "buy" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Wall Street Zen upgraded Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, March 11th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $535.00 price objective on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Fourteen research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $511.62.

Vertex Pharmaceuticals Stock Performance

VRTX stock opened at $466.36 on Wednesday. The firm has a market cap of $119.76 billion, a PE ratio of -118.97 and a beta of 0.41. The company has a quick ratio of 2.29, a current ratio of 2.65 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average of $449.35 and a 200-day moving average of $459.33. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 EPS for the quarter, missing the consensus estimate of $4.29 by ($0.23). Vertex Pharmaceuticals had a negative net margin of 8.91% and a negative return on equity of 3.36%. The firm had revenue of $2.77 billion during the quarter, compared to analysts' expectations of $2.85 billion. During the same quarter in the previous year, the company posted $4.76 EPS. Vertex Pharmaceuticals's revenue for the quarter was up 2.6% on a year-over-year basis. As a group, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.